News & Updates

Treatment with the combination of gefitinib and chemotherapy appears to yield significant increases in progression-free survival (PFS), intracranial PFS, and overall survival in patients with untreated EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases as compared gefitinib monotherapy, according to the results of the phase III GAP BRAIN study.

Children diagnosed with asthma between ages 5 and 7 years may have an increased risk of developing type 1 diabetes (T1D) and inflammatory bowel diseases (IBD; Crohn’s disease and ulcerative colitis), a Danish nationwide registry study suggests.

Lung cancer screening based on a risk model is more cost-effective than the 2021 recommendation by the US Preventive Services Task Force (USPSTF), meriting further consideration for the former, reports a recent study.

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.

Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.

Reduced lung function, regardless of smoking status, contributes to an increased hypertension prevalence, reports a study.